Paid Clinical Trials in Phoenix, AZ

As of June 2026, 933 paid clinical trials are recruiting in Phoenix, Arizona. Compensation typically covers time, travel, and study visits, with stipends ranging from modest amounts for short outpatient studies to several thousand dollars for long or inpatient protocols.

Both patients with specific conditions and healthy volunteers can qualify. Most trials offer free study-related medical care alongside compensation.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: June 4, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

933 clinical trials

↓ Download CSV

A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

for High Grade Osteosarcoma

Drug: Cabozantinib

174 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: Up to 40

Code: NCT05691478·Phase 2, Phase 3·Recruiting

Apply to this trial

Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy

for Acute Myeloid Leukemia

9 locations incl. Phoenix

Sponsor: Norman J. Lacayo

Sex: All·Age: Up to 21

Code: NCT05101551·Phase 1·Recruiting

Apply to this trial

Wellness App for Sleep Disturbance in Hematological Cancer Patients

for Cancer

3 locations incl. Phoenix

Sponsor: The University of Texas Health Science Center at San Antonio

Sex: All·Age: 18+

Code: NCT05294991·Recruiting

Apply to this trial

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss

for Childhood Medulloblastoma

101 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: 4 - 21

Code: NCT05382338·Phase 3·Recruiting

Apply to this trial

(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer

for Breast Neoplasms

15 locations incl. Phoenix

Sponsor: Atossa Therapeutics, Inc.

Sex: Female·Age: 18+

Code: NCT05607004·Phase 2·Recruiting

Apply to this trial

A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

for Primary Generalized Tonic-Clonic Seizures

59 locations incl. Mobile

Sponsor: Xenon Pharmaceuticals Inc.

Sex: All·Age: 12+

Code: NCT05667142·Phase 3·Recruiting

Apply to this trial

Dopamine vs. Norepinephrine for Hypotension in Very Preterm Infants With Late-onset Sepsis

for Late-Onset Neonatal Sepsis

3 locations incl. Phoenix

Sponsor: Mount Sinai Hospital, Canada

Sex: All·Age: 21 Weeks - 32 Weeks

Code: NCT05347238·Recruiting

Apply to this trial

Pilot/Pivotal Study of DBS+Rehab After Stroke

for Stroke

10 locations incl. Phoenix

Sponsor: Enspire DBS Therapy, Inc.

Sex: All·Age: 21+

Code: NCT05701280·Recruiting

Apply to this trial

A Study to Follow Patients With Adult Growth Hormone Deficiency (AGHD) Treated With Sogroya® for Long Term Safety Information

for Adult Growth Hormone Deficiency

29 locations incl. Phoenix

Sponsor: Novo Nordisk A/S

Sex: All·Age: 18+

Code: NCT05718570·Enrolling By Invitation

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

for Advanced Esophageal Adenocarcinoma

Drug: Nivolumab

785 locations incl. Birmingham

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT05677490·Phase 3·Recruiting

Apply to this trial

Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer

for Breast Cancer

45 locations incl. Dothan

Sponsor: Stemline Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT05563220·Phase 1, Phase 2·Recruiting

Apply to this trial

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

for H3 K27M

67 locations incl. Phoenix

Sponsor: Jazz Pharmaceuticals

Sex: All·Age: All ages

Code: NCT05580562·Phase 3·Recruiting

Apply to this trial

Alleviant ALLAY-HF Study

for Heart Failure

53 locations incl. Birmingham

Sponsor: Alleviant Medical, Inc.

Sex: All·Age: 40+

Code: NCT05685303·Enrolling By Invitation

Comparative Effectiveness of Online 8-session CBT vs. 1-Session Empowered Relief for Chronic Pain - The PROGRESS Study

for Pain, Chronic

5 locations incl. Phoenix

Sponsor: Stanford University

Sex: All·Age: 18+

Code: NCT05612750·Recruiting

Apply to this trial

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

for Atrial Fibrillation (AF)

Drug: Abelacimab

150 locations incl. Birmingham

Sponsor: Anthos Therapeutics, Inc.

Sex: All·Age: 65+

Code: NCT05712200·Phase 3·Recruiting

Apply to this trial

Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

for Castrate Resistant Prostate Cancer

6 locations incl. Phoenix

Sponsor: Epigenetix, Inc.

Sex: All·Age: 18+

Code: NCT05488548·Phase 1·Recruiting

Apply to this trial

Impella ECP Study (ECP Study) and Impella ECP Continued Access Protocol

for High-Risk Percutaneous Coronary Intervention

32 locations incl. Phoenix

Sponsor: Abiomed Inc.

Sex: All·Age: 18 - 90

Code: NCT05334784·Enrolling By Invitation

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

for Advanced Melanoma

Drug: Tebentafusp

25 locations incl. Phoenix

Sponsor: Immunocore Ltd

Sex: All·Age: 18+

Code: NCT05549297·Phase 3·Recruiting

Apply to this trial

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

for Viral Lung Infection and Acute Respiratory Failure

68 locations incl. Mobile

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT05624450·Phase 3·Recruiting

Apply to this trial

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

for Triple Negative Breast Cancer

184 locations incl. Birmingham

Sponsor: Gilead Sciences

Sex: All·Age: 18+

Code: NCT05633654·Phase 3·Recruiting

Apply to this trial

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

for High Grade Epithelial Ovarian Cancer

37 locations incl. Phoenix

Sponsor: Genmab

Sex: All·Age: 18+

Code: NCT05579366·Phase 1, Phase 2·Recruiting

Apply to this trial

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

for Clinical Stage III Cutaneous Melanoma AJCC v8

Drug: Cabozantinib

222 locations incl. Phoenix

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05136196·Phase 2·Recruiting

Apply to this trial

His-Bundle Corrective Pacing in Heart Failure

for Right Bundle-Branch Block

14 locations incl. Phoenix

Sponsor: University of Rochester

Sex: All·Age: 18+

Code: NCT05265520·Recruiting

Apply to this trial

[18F]PI-2620 Phase 3 Histopathological Study

for Alzheimer Disease

25 locations incl. Phoenix

Sponsor: Lantheus Biosciences Ltd.

Sex: All·Age: 50+

Code: NCT05641688·Phase 3·Recruiting

Apply to this trial

RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial

for Adenocarcinoma of Lung

Drug: Durvalumab

10 locations incl. Phoenix

Sponsor: Masonic Cancer Center, University of Minnesota

Sex: All·Age: 18+

Code: NCT04105270·Phase 2·Recruiting

Apply to this trial

Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation

for Advanced NSCLC

Drug: Adagrasib

84 locations incl. Anchorage

Sponsor: Mirati Therapeutics Inc.

Sex: All·Age: 18+

Code: NCT05609578·Phase 2·Recruiting

Apply to this trial

Dazucorilant in Patients With Amyotrophic Lateral Sclerosis

for Amyotrophic Lateral Sclerosis

4 locations incl. Phoenix

Sponsor: Corcept Therapeutics

Sex: All·Age: 18+

Code: NCT05407324·Phase 2·Recruiting

Apply to this trial

A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue

for Pediatric Sarcoma, Refractory

22 locations incl. South Birmingham

Sponsor: Nationwide Children's Hospital

Sex: All·Age: 2 - 40

Code: NCT05634369·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria

for Chronic Kidney Disease

Drug: Finerenone

18 locations incl. Phoenix

Sponsor: Bayer

Sex: All·Age: 1 - 18

Code: NCT05457283·Phase 3·Recruiting

Apply to this trial

The Diabetes Prevention Program Outcomes Study AD/ADRD Project

for Diabetes

27 locations incl. Phoenix

Sponsor: Marinella Temprosa

Sex: All·Age: All ages·Accepts healthy volunteers

Code: NCT05704309·Enrolling By Invitation

Adverse Outcomes and Mortality in Liver Transplant

for End Stage Liver DIsease

1 location in Phoenix

Sponsor: Mayo Clinic

Sex: All·Age: 18+

Code: NCT05477277·Recruiting

Apply to this trial

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

for Colorectal Neoplasms

129 locations incl. Glendale

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Sex: All·Age: 18+

Code: NCT05253651·Phase 3·Recruiting

Apply to this trial

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

for Atherosclerotic Cardiovascular Disease in Patients With ESKD

Drug: Clazakizumab

164 locations incl. Decatur

Sponsor: CSL Behring

Sex: All·Age: 18+

Code: NCT05485961·Phase 2, Phase 3·Recruiting

Apply to this trial

International Multicentric Observational Study to Characterize Subpopulations of Patients With Autism Spectrum Disorder

for Autism Spectrum Disorder

9 locations incl. Phoenix

Sponsor: Stalicla SA

Sex: All·Age: 12 - 65

Code: NCT05590715·Recruiting

Apply to this trial

Stand & Move at Work II: Effectiveness and Implementation of a Worksite Wellness Program

for Sedentary Behavior

1 location in Phoenix

Sponsor: Arizona State University

Sex: All·Age: 18+·Accepts healthy volunteers

Code: NCT05485675·Recruiting

Apply to this trial

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

for Acute Myeloid Leukemia

Drug: Venetoclax

45 locations incl. Phoenix

Sponsor: PedAL BCU, LLC

Sex: All·Age: 29 Days - 21

Code: NCT05183035·Phase 3·Recruiting

Apply to this trial

Post-Market Study to Assess iTind Safety in Comparison to UroLift

for Benign Prostatic Hyperplasia (BPH)

15 locations incl. Phoenix

Sponsor: Olympus Corporation of the Americas

Sex: Male·Age: 50+

Code: NCT04757116·Recruiting

Apply to this trial

A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma

for Recurrent Squamous Cell Carcinoma

25 locations incl. Gilbert

Sponsor: Alpha Tau Medical LTD.

Sex: All·Age: 18+

Code: NCT05323253·Recruiting

Apply to this trial

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

for Prostate Cancer

32 locations incl. Birmingham

Sponsor: Janux Therapeutics

Sex: Male·Age: 18 - 100

Code: NCT05519449·Phase 1·Recruiting

Apply to this trial

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

for Locoregional Recurrence

Drug: Ribociclib

20 locations incl. Birmingham

Sponsor: Oana Danciu

Sex: All·Age: 18+

Code: NCT05467891·Phase 2·Recruiting

Apply to this trial